Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study.

Ma, Haiyan; Lim, Tien Huey; Leerapun, Apinya; Weltman, Martin; Jia, Jidong; Lim, Young-Suk; Tangkijvanich, Pisit; Sukeepaisarnjaroen, Wattana; Ji, Yun; Le Bert, Nina; Li, Dong; Zhang, Yao; Hamatake, Robert; Tan, Nicole; Li, Chunming; Strasser, Simone I; Ding, Huiguo; Yoon, Jung-Hwan; Stace, Nigel H; Ahmed, Tanvir; Anderson, Dave E; Yan, Li; Bertoletti, Antonio; Zhu, Qing; Yuen, Man-Fung

Ma, Haiyan; Lim, Tien Huey; Leerapun, Apinya; Weltman, Martin; Jia, Jidong; Lim, Young-Suk; Tangkijvanich, Pisit; Sukeepaisarnjaroen, Wattana; Ji, Yun; Le Bert, Nina; Li, Dong; Zhang, Yao; Hamatake, Robert; Tan, Nicole; Li, Chunming; Strasser, Simone I; Ding, Huiguo; Yoon, Jung-Hwan; Stace, Nigel H; Ahmed, Tanvir; Anderson, Dave E; Yan, Li; Bertoletti, Antonio; Zhu, Qing; Yuen, Man-Fung.

Afiliación

Ma H; Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore.
Lim TH; Middlemore Hospital, Auckland, New Zealand.
Leerapun A; Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand.
Weltman M; Nepean Hospital, Kingswood, Australia.
Jia J; Beijing Friendship Hospital, Beijing, China.
Lim YS; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Tangkijvanich P; Center of Excellence in Hepatitis and Liver Cancer, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Sukeepaisarnjaroen W; Srinagarind Hospital, Khon Kaen, Thailand.
Ji Y; Brii Biosciences Inc. Durham, NC, USA.
Le Bert N; Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore.
Li D; Brii Biosciences Inc. Beijing, PR China.
Zhang Y; Brii Biosciences Inc. Beijing, PR China.
Hamatake R; Brii Biosciences Inc. Durham, NC, USA.
Tan N; Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore.
Li C; Brii Biosciences Inc. Beijing, PR China.
Strasser SI; Royal Prince Alfred Hospital, Camperdown, Australia.
Ding H; Beijing You 'an Hospital affiliated to Capital Medical University, Beijing, China.
Yoon JH; Seoul National University Hospital, Seoul, South Korea.
Stace NH; Capital & Coast District Health Board, Wellington, New Zealand.
Ahmed T; VBI Vaccines, Cambridge, MA, USA.
Anderson DE; VBI Vaccines, Cambridge, MA, USA.
Yan L; Brii Biosciences Inc. Durham, NC, USA.
Bertoletti A; Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore.
Zhu Q; Brii Biosciences Inc. Durham, NC, USA.
Yuen MF; Department of Medicine and State Key Laboratory of Liver Research, The University of Hong Kong, Queen Mary Hospital, Hong Kong.

JHEP Rep ; 3(6): 100361, 2021 Dec.

Article en En | MEDLINE | ID: mdl-34661089

Palabras clave

AE, adverse event; ALT, alanine aminotransferase; Anti-HBs, hepatitis B surface antibody; BMI, body mass index; BRII-179; CHB; CHB, chronic hepatitis B; ELISpot, enzyme-linked immune absorbent spot; HBV, hepatitis B virus; HBV-specific immune response; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; IFN-alpha; IFN-α, interferon-α; IM, intramuscular; IU, international units; NA, nucleos(t)ide analogue; PBMCs, peripheral blood mononuclear cells; PEG-IFN-α, pegylated interferon-α; SAE, serious adverse events; Th1, T helper type 1; immunotherapy

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: JHEP Rep Año: 2021 Tipo del documento: Article País de afiliación: Singapur

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google